Cosmos Health reports preliminary $54.3 million nine-month revenue
- Cosmos Health reported preliminary nine-month revenue of approximately $54.3 million, marking a 19% increase over the same period in 2025.
- Following the preliminary financial revenue update, the company's share price traded around $0.32.
- The company reaffirmed its expected 2026 revenue of over $90 million, anticipating its highest-ever fourth-quarter performance.
Cosmos Health (NASDAQ:COSM) reported preliminary nine-month revenue of approximately $54.3 million for the period ended September 30, 2026.
The 19% year-over-year revenue increase built upon the $45.6 million recorded in 2025, sitting 35% above the levels achieved in 2024.
Preliminary third-quarter revenue reached approximately $17.4 million, representing a 2% gain over 2025 and a 40% jump compared to 2024.
The company noted that every single quarter of 2026 has successfully exceeded its respective historical corresponding-quarter revenue record.
Following the preliminary financial announcement, the Cosmos Health share price traded at $0.32.
Operational drivers included Cana Laboratories pushing its production pipeline past 32.7 million units alongside peak distribution volumes at CosmoFarm.
Management reaffirmed its full-year 2026 revenue target of over $90 million—representing roughly 38% growth over 2025—backed by expectations for a record-breaking fourth quarter.
Frequently asked questions
More from United States
AbbVie revenue increases 10.3% to $17.4 billion in third quarter
Sensient Q3 revenue rockets 10.6% to $455.8 million
Cameco Q3 adjusted loss reaches CA$2 million as uranium output falls
Kite Realty Q3 loss narrows to $13.3 million as NOI grows
Largo cuts 2026 vanadium production outlook to 9,500–10,500 tonnes
nVent Q3 sales jump 44% as shares fall despite higher revenue
